Plant ID: NPO5649
Plant Latin Name: Coptis chinensis
Taxonomy Genus: Coptis
Taxonomy Family: Ranunculaceae
NCBI TaxonomyDB:
261450
Plant-of-the-World-Online:
710313-1
Anaesthetic; Analgesic; Antibacterial; Antidote; Antipyretic; Antispasmodic; Bitter; Blood tonic; Carminative; Cholagogue; Digestive; Sedative; Skin; Stomachic; Tonic; Vasodilator
China
TSHR; | |
ADRA2C; ADRA2B; DRD1; CHRM1; HTR2B; | |
RECQL; AKR1B1; AKR1B10; | |
GAA; BCHE; ACHE; | |
MAPK1; | |
CA2; CA1; CA12; CA9; CA14; CA7; CA5A; CA6; | |
HIF1A; | |
HTT; LMNA; RAD52; F3; SIGMAR1; | |
SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
Small molecule receptor (family A GPCR) | CHRM1 | Muscarinic acetylcholine receptor M1 | P11229 | CHEMBL216 |
Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | RAD52 | DNA repair protein RAD52 homolog | P43351 | CHEMBL2362978 |
Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.733E-13 | 9.435E-10 | CA1, CA12, CA2, CA5A, CA6, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.056E-10 | 3.832E-07 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 9.890E-07 | 1.282E-03 | CYP1A2, CYP2C19, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 9.890E-07 | 1.282E-03 | CYP1A2, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.001E-06 | 1.282E-03 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.364E-06 | 1.563E-03 | BCHE, CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 2.830E-06 | 2.117E-03 | ACHE, BCHE |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 3.412E-06 | 2.397E-03 | AKR1B1, AKR1B10, CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
BP | GO:0009987; cellular process | GO:0007189; adenylate cyclase-activating G-protein coupled receptor signaling pathway | 6.690E-06 | 3.937E-03 | ADRA2B, ADRA2C, DRD1, TSHR |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 8.482E-06 | 4.104E-03 | CYP2D6, CYP3A4 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 8.482E-06 | 4.104E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.860E-06 | 4.104E-03 | CYP1A2, CYP2D6, CYP3A4 |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 8.482E-06 | 4.104E-03 | ADRA2B, ADRA2C |
CC | GO:0044464; cell part | GO:0042995; cell projection | 1.120E-05 | 4.910E-03 | ADRA2C, AKR1B1, CA2, CHRM1, DRD1, HIF1A, HTR2B, HTT, MAPK1, SMN1, SMN2 |
BP | GO:0032501; multicellular organismal process | GO:0007399; nervous system development | 1.607E-05 | 5.967E-03 | ACHE, CHRM1, SIGMAR1, SMN1, SMN2, TSHR |
BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.695E-05 | 5.967E-03 | ADRA2B, ADRA2C |
BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.695E-05 | 5.967E-03 | ADRA2B, ADRA2C |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.695E-05 | 5.967E-03 | CYP1A2, CYP3A4 |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 2.562E-05 | 8.327E-03 | CA2, CA7, DRD1, HTR2B, HTT |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 2.622E-05 | 8.396E-03 | CYP2C19, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.847E-19 | 4.021E-15 | CA1, CA12, CA14, CA2, CA5A, CA6, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.919E-15 | 5.355E-11 | CA1, CA12, CA14, CA2, CA5A, CA6, CA7, CA9 |
CC | GO:0044464; cell part | GO:0043005; neuron projection | 4.415E-05 | 1.248E-02 | ADRA2C, CA2, CHRM1, HTR2B, HTT, MAPK1, SMN1, SMN2 |
CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 1.848E-04 | 3.382E-02 | SMN1, SMN2 |
CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 2.020E-04 | 3.605E-02 | AKR1B1, HIF1A, MAPK1 |
CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 2.182E-04 | 3.801E-02 | SMN1, SMN2 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 5.270E-19 | 6.746E-17 | CA12, CA1, CA2, CA5A, CA7, CA6, CA9, CA14 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 4.922E-06 | 2.308E-04 | CYP2D6, CYP1A2, CYP3A4, CYP2C19 |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 5.408E-06 | 2.308E-04 | CHRM1, HTR2B, DRD1, ADRA2C, ADRA2B, TSHR |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 3.364E-05 | 7.177E-04 | CYP2D6, HTR2B, MAPK1, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.452E-05 | 4.126E-04 | CYP1A2, CYP3A4, CYP2C19 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 1.612E-05 | 4.126E-04 | AKR1B10, GAA, AKR1B1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 3.104E-04 | 4.717E-03 | CHRM1, MAPK1, DRD1, TSHR |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.353E-04 | 4.302E-03 | CYP2D6, CYP1A2, CYP3A4 |
09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 8.041E-04 | 9.356E-03 | ACHE, CHRM1, MAPK1 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 4.082E-04 | 5.225E-03 | HTR2B, MAPK1, DRD1 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.316E-04 | 4.717E-03 | CYP1A2, CYP3A4, CYP2C19 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; DRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; DRD1; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | F3; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
C00-D49: Neoplasms | Cancer | C00-C96 | ACHE; MAPK1; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; DRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |